Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arvor
Cambridge, Massachusetts, United Statesarvor.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Arbor Biotechnologies is a next-generation gene editing company developing curative genetic medicines using its proprietary suite of programmable DNA editors. Its lead asset ABO-101 targets primary hyperoxaluria type 1 and has entered Phase 1/2 clinical trials. The pipeline leverages advanced genome-editing technologies to address both rare and common genetic disorders with high unmet need—especially those affecting the liver and CNS—using approaches that go beyond traditional CRISPR methods by enabling knockouts, excisions, insertions, and reverse transcriptase-mediated edits.
- Therapeutic areas
- GastroenterologyRare DiseasesNeurology
- Modalities
- Gene therapyCRISPR-based therapyGenome editing technology (including gene knockout, excision, reverse transcriptase editing, large gene insertion)Potentially other nucleic acid-based modalities (based on proprietary DNA editors)
- Industry
- Biotech
02
Partnerships
Vertex Pharmaceuticals – expanded partnership includes ex vivo engineered cell therapiesLonza – licensing deal for gene editing technologyEdigene – license agreement to advance ex vivo engineered cell therapies
Beyond the preview
Go deeper on Arvor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arvor.